Pain Syndrome Removing at Patients with Temporomandibular Joint Disorders and Urinary System
Actuality of using the nonsteroidal anti-inflammatory drugs for complex temporomandibular joint (TMJ) degenerative-dystrophic disorders treatment acquiring further more significance due to increasing of this widespread pathology among the different gender and age of person. Offered results of using the selective cyclooxygenase (COX-2) inhibitors drug – orodispersible form of Meloxicam for patient with TMJ osteoarthritis and urinary diseases. Decreasing of the TMJ pain syndrome either during chewing or calm state, jaws activity volume was improved, crackling and crepitation at the joint were decreased. Effectiveness and safety of using the orodispersible tablets of Meloxicam for treatment of TMJ osteoarthritis were estimated.
